Inactive Instrument

Neuralstem, Inc. Stock Nasdaq

US64127R4011

Latest news : Neuralstem, Inc.

06-11	Palisade Bio, Inc. Announces Board Appointments	CI
05-13	Palisade Bio Inc - may offer and sell up to $300 million of securities - SEC filing	RE
05-13	Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis	CI
03-31	Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease	MT
03-31	Palisade Bio Says Phase 1b Data Supports PALI-2108's Development as Potential Treatment for Fibrostenotic Crohn's Disease	MT
03-31	Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn?s Disease	CI
03-27	Palisade Bio, Inc. announced that it has received $3 million in funding from Iterative Scopes, Inc.	CI
03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
03-21	Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
02-23	Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026	CI
02-18	Palisade Bio, Inc. Appoints Bram Verstockt to Clinical Advisory Board	CI

More news

Analysts' recommendations: Neuralstem, Inc.

03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
17/11/23	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT
16/05/23	Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	MT

More recommendations

Press Releases: Neuralstem, Inc.

06-11	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
06-10	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ
06-09	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium	AQ
05-27	Palisade Bio to Participate in the Jefferies Global Healthcare Conference	AQ
05-13	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108	AQ

More press releases

News in other languages: Neuralstem, Inc.

30/01/24	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
29/01/24	LATE BRIEFING - Unternehmen und Märkte
29/01/24	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
29/01/24	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
29/01/24	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	328M 288M 265M 248M 465M 30.95B 475M 3.19B 1.23B 15.29B 1.23B 1.2B 53.04B	P/E 2026 *	-7.88x	P/E 2027 *	-6.58x
Enterprise Value	234M 205M 189M 177M 332M 22.06B 339M 2.27B 879M 10.9B 878M 859M 37.81B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	-	-
Net income	-52.49M -46.02M -42.42M -39.71M -74.47M -4.95B -76.02M -510M -197M -2.45B -197M -193M -8.49B	-65.04M -57.03M -52.57M -49.21M -92.28M -6.14B -94.2M -632M -244M -3.03B -244M -239M -10.51B
Net Debt	-94.2M -82.59M -76.13M -71.28M -134M -8.89B -136M -915M -354M -4.39B -354M -346M -15.23B	-331M -290M -268M -251M -470M -31.24B -480M -3.22B -1.24B -15.44B -1.24B -1.22B -53.54B

Neuralstem, Inc. Stock Nasdaq

Stocks

US64127R4011

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Quotes and Performance

Financials

Company Profile